SG Americas Securities LLC Acquires 8,387 Shares of Definitive Healthcare Corp. (NASDAQ:DH)

SG Americas Securities LLC grew its stake in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 44.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,189 shares of the company’s stock after acquiring an additional 8,387 shares during the period. SG Americas Securities LLC’s holdings in Definitive Healthcare were worth $112,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA grew its stake in Definitive Healthcare by 36.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after acquiring an additional 1,626,813 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Definitive Healthcare in the 3rd quarter valued at $512,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Definitive Healthcare by 34.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock valued at $209,000 after purchasing an additional 12,946 shares during the period. Barclays PLC grew its position in shares of Definitive Healthcare by 318.8% during the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock valued at $366,000 after purchasing an additional 62,354 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Definitive Healthcare by 29.4% in the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after purchasing an additional 317,952 shares during the period. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock opened at $5.24 on Thursday. The firm has a market capitalization of $605.32 million, a PE ratio of -1.69, a price-to-earnings-growth ratio of 3.94 and a beta of 1.45. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare Corp. has a 12 month low of $3.19 and a 12 month high of $10.62. The business’s 50-day moving average price is $4.50 and its 200-day moving average price is $4.40.

Insiders Place Their Bets

In other news, insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the transaction, the insider now owns 433,830 shares in the company, valued at approximately $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.84% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on DH shares. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Stephens assumed coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target on the stock. Finally, Barclays reissued an “underweight” rating and set a $4.00 price objective on shares of Definitive Healthcare in a report on Monday, January 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and an average price target of $5.72.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.